Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
expanded and activated autologous natural killer cells
- Development stage
- Phase 1
- Lead developer
- Hospital Universitario 12 de Octubre
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Expanded and activated autologous natural killer cells (NKAE cells) is an autologous cell therapy developed by Dr. Joaquín Martínez López and colleagues at Hospital Universitario 12 de Octubre. The therapy involves the ex vivo expansion and activation of a patient's own natural killer (NK) cells, typically derived from peripheral blood, using irradiated feeder cells such as K562-mb15-41BBL or Clone9.mbIL21. These activated cells are then reinfused into the patient to target and eliminate malignant cells. In the context of multiple myeloma, NKAE cells utilize natural cytotoxicity receptors, including NKG2D and NKp30, to recognize and kill myeloma cells. This therapy has been investigated in Phase 1 clinical trials (e.g., NCT02481934) as a consolidation treatment for patients with relapsed or refractory multiple myeloma, often in combination with immunomodulatory drugs like lenalidomide or proteasome inhibitors like bortezomib.
- Other names
- activated and expanded autologous natural killer cellsautologous NKAE cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on expanded and activated autologous natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on expanded and activated autologous natural killer cells.